-
31) Belz GG. Elastic properties
and Windkessel function of the human aorta. Cardiovasc Drugs
Ther 1995; 9:73-83. (
Original-Artikel;
PDF)
-
32) Schroeter V, Belz GG. Kardiale
Aspekte der klinischen Anwendung von H1-Rezeptorantagonisten.
Münch Med
Wochenschr 1997; 139:550-553.
-
33) Lehmann ED, Belz GG. A role
for aortic biophysical measurements in vivo.
J Noninvasiv Cardiol 1998; 3:19-22.
-
34) Breithaupt-Grögler K, Belz GG. Epidemiology
of the arterial stiffness. Path Biol 1999; 47:604-613.
-
35) Unger T, Azizi M, Belz GG. Blocking
the tissue renin-angiotensin system: the future cornerstone of
therapy. J Hum Hypertension 2000; 14(Suppl.2):S23-S31.
-
36) Belz GG., Man in't Veld AJ. Differences
among angiotensin II receptor antagonists: choosing the optimal
agent in clinical practice. Eur Heart J Supplements 2000; 2 (Suppl.B):B8-B12.
-
37) Belz GG., Breithaupt-Grögler
K, Osowski U. Treatment
of congestive heart failure – current status of use of
digitoxin. Eur J Clin Invest 2001; 31(Suppl.2):10-17.
-
38) Belz GG., Loew D. Dose-response
related efficacy in orthostatic hypotension of a fixed combination
of D-camphor and an extract from fresh Crataegus Berries and
the contribution of the single components. Phytomedicine 2003; 10(Suppl.IV):61-67.
-
39) Belz GG. Angiotensin II
dose-effect curves and Schild regression plots for characterization
of different angiotensin II AT1 receptor antagonists in clinical
pharmacology. Br J Clin Pharm 2003; 56:3-10. (
Original-Artikel;
PDF)
-
40) Belz GG., Mohr-Kahaly S. Kakao und dunkle Schokolade zur kardiovaskulären Prävention? Dtsch Med Wochenschr. 2011; 136:2657-63.
-
41) Eichhorn A, Lochner S, Belz GG. Vitamin D zur Prävention von Erkrankungen? Dtsch. Med. Wochenschr. 2012; 137:906-912
-
42 ) Worm N, Belz GG., Stein-Hammer C. Moderater Weingenuss und Prävention der koronaren Herzkrankheit. Die Entwicklung der Evidenz. Dtsch. Med. Wochenschr. 2013; 138:2653-2657.
-